HDFC Securities Pick of the Week 18th Jan'26: Ipca Laboratories Ltd

HDFC Securities has selected Ipca Laboratories Ltd. (NSE: IPCALAB) — a leading player in the Indian pharmaceutical market — as its Pick of the Week. The brokerage recommends buying the stock in the ₹1500–1535 range and adding on dips in the ₹1350–1359 band. HDFC Securities has assigned a base case fair value of ₹1647 and a bull case fair value of ₹1780 over a 2–3 quarter time horizon, supported by strong domestic formulation growth, revival in US business post US FDA clearance, API leadership, and synergy benefits from the Unichem acquisition.

Q2FY26 Result: Healthy Growth with Margin Expansion

Ipca Laboratories reported strong performance in Q2FY26, with revenue and profits exceeding expectations. Consolidated revenue grew 8.6% YoY to ₹2,557 crore, supported by healthy growth in domestic formulations and API exports, while operating margins expanded 210bps YoY to 20.9%.

Key Financials – Q2FY26

• Revenue: ₹2,557 crore; up 8.6% YoY, 10.7% QoQ
• EBITDA: ₹545 crore; margin at 20.9%
• Net Profit (Adj.): ₹471 crore; up 23% YoY
• Domestic Formulation Revenue: ₹1,019 crore; up ~8% YoY
• API Revenue: ₹408 crore; up 28% YoY
• International Formulation Revenue: ₹493 crore; down 9% YoY
• Subsidiary Revenue (mainly Unichem Labs): ₹626 crore; up 15% YoY

Strategic Growth Drivers and Key Strengths

1. Robust Domestic Formulation Growth
   Domestic formulations (~40% of sales) grew steadily, driven by chronic and acute therapy segments such as pain management, cardiology, and dermatology. Strong brand equity and consistent new product launches support sustained growth.
2. Revival of US and EU Business
   With US FDA clearance for three manufacturing facilities, Ipca is set to scale its US operations. The company plans phased product launches from its ANDA portfolio over the next 12–18 months. European business remains stable, with focused efforts to expand footprint and tender participation.
3. API Leadership and Backward Integration
   API business contributed ~15% to revenue in H1FY26, with strong exports to Europe and Latin America. Leadership in key molecules such as sartans, atenolol, and hydroxychloroquine ensures cost competitiveness and backward integration benefits.
4. Synergies from Unichem Acquisition
   The acquisition of Unichem Labs expands Ipca’s presence in the US and Brazil and enables operational synergies, including cross-selling APIs, optimizing procurement, and leveraging distribution networks, enhancing margins and growth prospects.
5. Strong Therapeutic Portfolio
   Top domestic brands like Zerodol, CTD-T, Folitrax, and Pacimol continue to outperform therapy and market growth, reflecting strong brand-building and physician coverage. Chronic therapies now contribute ~35% of domestic revenue, with continued expansion expected.

Valuation & Recommendation

HDFC Securities’ Estimates

• Base Case Fair Value: ₹1,647
• Bull Case Fair Value: ₹1,780
• Time Horizon: 2–3 quarters

Recommendation

• Buy in the ₹1,500–1,535 range
• Add on dips at ₹1,350–1,359

At the current price of ₹1,510, the stock trades at ~21x FY28E EPS, offering attractive risk-reward supported by strong domestic growth, API leadership, and US business revival.

Risks & Considerations

• Delay in ramping up acquired Unichem portfolio or achieving synergies
• Inclusion of key drugs under NLEM impacting domestic formulation revenue
• Regulatory or compliance challenges in the US, EU, or other international markets
• Currency fluctuations affecting international revenue
• Price erosion in US generics market

HDFC Securities View

Ipca Laboratories is a structurally strong pharmaceutical play with a well-diversified product portfolio, strong domestic market positioning, and leadership in API manufacturing. The combination of robust domestic growth, revival in regulated markets, and operational synergies from Unichem positions the company for sustainable medium-term growth. With improving margins, consistent brand performance, and strong R&D capabilities, Ipca Laboratories remains an attractive investment opportunity for investors seeking exposure to high-quality Indian pharmaceutical companies.